Effect of artesunate on expression of heat shock protein 47 in mice with liver fibrosis induced by Schistosoma japonicum

doi:10.12140/j.issn.1000-7423.2019.02.001

Abstract

Abstract:

Objective To understand the possible mechanism underlying the artesunate’s inhibition on Schistosoma japonicum-induced hepatic fibrosis, the effect of artesunate on the expression of heat shock protein 47 (HSP47) in serum and liver during the early stage of mouse hepatic fibrosis induced by S. japonicum infection was studied. Methods Total 30 female ICR mice were randomly divided into 3 groups: the un-infected control group, the infection group and the treatment group (infection + artesunate treatment), with 10 mice in each group. Each mouse in the infection and treatment groups was infected with 20 ± 1 cercariae of S. japonicum via abdomen skin penetration. All infected mice were treated with 300 mg/kg praziquantel for 2 days to eliminate the adult worms and the mice in treatment group were additionally treated with 60 mg/kg artesunate in 0.3 ml volume by intraperitoneal injection daily for 2 weeks. For the control group, mice were given the same volume of saline. After the artesunate treatment, all mice from 3 groups were sacrificed, blood samples were taken for serum separation, and the levels of HSP47 and transforming growth factor-β1(TGF-β1) in sera were detected by ELISA. The mouse livers and spleens were collected and weighed to calculate their organ index(organ weight/body weight). The livers were fixed with paraformaldehyde and sectioned for hematoxylin eosin (HE) and Masson-trichrome staining to observe the liver pathological changes and collagen proliferation. The hydroxyl-proline level in liver was measured using the alkaline hydrolysis. The mRNA expression levels of liver HSP47 and type Ⅰ collagen (COL1) were determined by real-time quantitative PCR (RT-PCR). Results The liver index in infection group (10.50 ± 0.57) was significantly higher than that in treatment group (8.31 ± 0.52) and in un-infected control group (4.72 ± 0.52) with statistical difference (P < 0.01). The spleen index was significantly higher in infection group (2.41 ± 0.44) than that in un-infected control group (0.38 ± 0.04) (P < 0.01), however it was not significantly different compared to that in treatment group(P > 0.05). Liver pathological damage was significantly reduced in treatment group compared to the infection group, including reduced liver size and egg granuloma. Masson-trichrom staining showed less liver fibrosis in treatment group than in infection group. The area of collagen proliferation in liver in treatment group was (6.87 ± 3.54)%, that is significantly smaller than that in infection group [(25.78 ± 2.61)%] (P < 0.01). The levels of HSP47 and TGF-β1 in sera of mice in the treatment group [(169.81 ± 20.94) pg/ml and (20.82 ± 1.90) ng/ml, respectively] were significantly lower than that in infection group [(203.14 ± 46.29) pg/ml and (27.49 ± 6.81) ng/ml] (P < 0.05), even though the levels of HSP47 and TGF-β1 in both infection and treatment groups were significantly higher than that in the un-infected control group (P < 0.01). The similar results were also observed in the hydroxyproline level and the expression of HSP47 and COL1 in liver tissues. The level of liver hydroxyproline in the treatment group was (0.27 ± 0.08) mg/g, which was significantly lower than that of the infection group [(0.69 ± 0.07) mg/g] (P < 0.01), however, all higher than that in un-infected control group [(0.11 ± 0.04) mg/g] (P < 0.05). The mRNA expression levels of HSP47 and COL1 in the liver of mice of treatment group were 0.49 ± 0.27 and 0.67 ± 0.09, respectively, which are significantly lower than those in the infection group (0.84 ± 0.17 and 0.91 ± 0.11, respectively) (P < 0.05). The expression levels of HSP47 and COL1 in both infection and treatment groups were significantly higher than those in the un-infected control group (0.24 ± 0.04 and 0.24 ± 0.05) (P < 0.01). The serum HSP47 level was positively correlated with the level of TGF-β1 (r = 0.928 0), and serum HSP47 level and TGF-β1 level were positively correlated with the level of hepatic COL1 mRNA expression(r = 0.926 2, 0.872 8). Conclusion Artesunate has protective effects on the early hepatic fibrosis caused by S. japonicum infection and the protection is possibly achieved by down-regulating the expression of HSP47, further suppressing the collagen synthesis so as to alleviate the hepatic fibrosis. HSP47 is expected to be one of the new prognostic markers and treatment targets in S. japonicum infection.

Key words: Heat shock protein 47, Artesunate, Liver fibrosis, Schistosoma japonicum

CLC Number:

R532.21

Yong-hua ZHOU, Chen XU, Ying-ying YANG, Chun-gang ZHOU, Cong-jin MEI, Xue SAI, Yong-liang XU, Jun-qi YANG, Li-juan SHEN. Effect of artesunate on expression of heat shock protein 47 in mice with liver fibrosis induced by Schistosoma japonicum[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2019, 37(2): 115-121.

Figures/Tables 2

References 23

[1]	Tao R, Fan XX, Yu HJ, et al. MicroRNA-29b-3p prevents Schistosoma japonium-induced liver fibrosis by targeting Col1A1 and col3A1[J]. J Cell Biochem, 2018, 119(4): 3199-3209.
[2]	姜鹏月, 潘卫庆. 血吸虫病肝纤维化及其致病机制的研究进展[J]. 中国热带医学, 2018, 18(8): 847-852.
[3]	Coutinho HM, Acosta LP, Wu HW, et al. The cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection[J]. J Infect Dis, 2007, 195(2): 288-295.
[4]	王勇. 后血吸虫病传播阻断阶段: 肝纤维化问题[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(6): 404-406.
[5]	周永华, 杨莹莹, 范小琳, 等. Th17/Treg免疫失衡在血吸虫病肝纤维化中的作用[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(1): 89-92.
[6]	Colley DG, Bustinduy AL, Secor WE, et al. Humanschistosomiasis[J]. Lancet, 2014, 383(9936): 2253-2264.
[7]	Kumar A, Bhandari, Sarde SJ, et al. Ancestry molecular evolutionary analyses of heat shock protein 47 kDa(HSP47/serpinh1)[J]. Sci Rep, 2017, 7(1): 10394.
[8]	Ito S, Nagata K.Biology of Hsp47 (Serpin H1), a collagen-specific molecular chaperone[J]. Semin Cell Dev Biol, 2017, 62(2): 142-151.
[9]	Ishida Y, Nagata K.Hsp47 as a collagen-specific molecular chaperone[J]. Methods Enzymol, 2011, 499(5): 167-182.
[10]	Otsuka M, Shiratori M, Chiba H, et al. Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes[J]. Exp Lung Res, 2017, 43(6/7): 271-282.
[11]	Chu H, Wu T, Wu W, et al. Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis[J]. Protein Cell, 2015, 6(8): 589-598.
[12]	Huang JQ, Tao R, Li L, et al. Involvement of heat shock protein 47 in Schistosoma japonicum-induced hepatic fibrosis in mice[J]. Int J Parasitol, 2014, 44(1): 23-35.
[13]	Zhao Y, Dang Z, Xu S, et al. Heat shock protein 47 effects on hepatic stellate cell-associated receptors in hepatic fibrosis of Schistosoma japonicum-infected mice[J]. Biol Chem, 2017, 398(12): 1357-1366.
[14]	刘旭. 青蒿琥酯预防感染日本血吸虫的研究[J]. 中国寄生虫学与寄生虫病杂志, 2001, 19(1): 52-53.
[15]	胡水银, 刘骏, 汪斌. 青蒿琥酯对防汛人群预防日本血吸虫感染的效果[J]. 中国寄生虫学与寄生虫病杂志, 2000, 18(2): 113-114.
[16]	Zhou YH, Sai X, Xu YL, et al. Investigation on the role and mechanisms of artesunate against Schistosoma japonicum-induced liver fibrosis[J]. Trop Med Int Health, 2015, 20(SⅠ): 235.
[17]	杜岩, 李立楠, 方步武. 青蒿琥酯抑制肝纤维化的作用及其机制[J]. 中国应用生理学杂志, 2015, 31(1): 14-17.
[18]	陈艳, 肖政. 白藜芦醇及其伍用吡喹酮对小鼠日本血吸虫肝纤维化的治疗作用[J]. 中国寄生虫学与寄生虫病杂志, 2013, 31(5): 337-341.
[19]	SHakir L, Hussain M, Javeed A, et al. Arteminins and immune system[J]. Eur J Pharmacol, 2011, 668(1/2): 6-14.
[20]	邓菊红, 陶然, 宋启琴, 等. 热休克蛋白47-ShRNA调节肝星状细胞膜受体对日本血吸虫鼠肝纤维化的影响[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(4): 317-324.
[21]	Morry J, Ngamcherdtrakul W, Gu S.Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis[J]. Biomaterials, 2015, 66(10): 41-52.
[22]	Zhu Y, Li Z, Wang Y,et al. Overexpression of miR-29b reduces collagen biosynthesis by inhibiting heat shock protein 47 during skin wound healing[J]. Transl Res, 2016, 178(12): 38-53.e6.
[23]	Zhang Y, Ghazwani M, Li J, et al. MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase[J]. Biochem Biophys Res Commun, 2014, 446(4): 940-944.

基因名称 Gene name	引物序列 Primer sequence	产物大小/bp Product size/bp
HSP47	F: 5′-ACCGAGCCCTCTTCAGTCTT-3′	184
	R: 5′-GGTGATGCCCAACATAACAAT-3′
COL1A1	F: 5′-CGCCATCAAGGTCCTACTGC-3′	152
	R: 5′-ACGGGAATCCATCGGTCA-3′
GAPDH	F: 5′-CCTTCCGTGTTCCTACCC-3′	130
	R: 5′-CCCAAGATGCCCTTCAGT-3′